MY209356A - A xinafoate salt of a jak inhibiting compound - Google Patents
A xinafoate salt of a jak inhibiting compoundInfo
- Publication number
- MY209356A MY209356A MYPI2021000231A MYPI2021000231A MY209356A MY 209356 A MY209356 A MY 209356A MY PI2021000231 A MYPI2021000231 A MY PI2021000231A MY PI2021000231 A MYPI2021000231 A MY PI2021000231A MY 209356 A MY209356 A MY 209356A
- Authority
- MY
- Malaysia
- Prior art keywords
- inhibiting compound
- xinafoate salt
- formula
- jak
- jak inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699955P | 2018-07-18 | 2018-07-18 | |
| US201962866013P | 2019-06-25 | 2019-06-25 | |
| PCT/EP2019/069252 WO2020016302A1 (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY209356A true MY209356A (en) | 2025-07-03 |
Family
ID=67396927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021000231A MY209356A (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11149029B2 (https=) |
| EP (1) | EP3823964A1 (https=) |
| JP (2) | JP7422732B2 (https=) |
| KR (1) | KR102849420B1 (https=) |
| CN (2) | CN118580223A (https=) |
| AU (1) | AU2019304014B2 (https=) |
| BR (1) | BR112021000467A2 (https=) |
| CA (1) | CA3105585A1 (https=) |
| IL (1) | IL280025B2 (https=) |
| MA (1) | MA53162A (https=) |
| MX (1) | MX2021000611A (https=) |
| MY (1) | MY209356A (https=) |
| SG (1) | SG11202100240RA (https=) |
| WO (1) | WO2020016302A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009031011A2 (en) | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
| MX2013003019A (es) * | 2010-09-15 | 2013-05-28 | Hoffmann La Roche | Compuestos de azabenzotiazol, composiciones y metodos de uso. |
| AU2014342338B2 (en) * | 2013-11-01 | 2016-12-01 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
| PL3189045T3 (pl) | 2014-08-11 | 2022-04-04 | Sun Pharmaceutical Industries Limited | Nowe sole nilotynibu i jego polimorfy |
| BR112018005833B1 (pt) * | 2015-09-25 | 2023-10-10 | Dizal (Jiangsu) Pharmaceutical Co., Limited | Composto, sal farmaceuticamente aceitável, composição farmacêutica e uso do composto |
| KR102585048B1 (ko) | 2017-01-17 | 2023-10-05 | 아스트라제네카 아베 | Jak1 선택적 억제제 |
| CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
-
2019
- 2019-07-17 SG SG11202100240RA patent/SG11202100240RA/en unknown
- 2019-07-17 EP EP19742558.0A patent/EP3823964A1/en active Pending
- 2019-07-17 AU AU2019304014A patent/AU2019304014B2/en active Active
- 2019-07-17 CN CN202410624343.9A patent/CN118580223A/zh active Pending
- 2019-07-17 MA MA053162A patent/MA53162A/fr unknown
- 2019-07-17 MY MYPI2021000231A patent/MY209356A/en unknown
- 2019-07-17 US US16/513,781 patent/US11149029B2/en active Active
- 2019-07-17 JP JP2021502626A patent/JP7422732B2/ja active Active
- 2019-07-17 CN CN201980047093.4A patent/CN112424187B/zh active Active
- 2019-07-17 KR KR1020217001860A patent/KR102849420B1/ko active Active
- 2019-07-17 MX MX2021000611A patent/MX2021000611A/es unknown
- 2019-07-17 WO PCT/EP2019/069252 patent/WO2020016302A1/en not_active Ceased
- 2019-07-17 BR BR112021000467-0A patent/BR112021000467A2/pt unknown
- 2019-07-17 CA CA3105585A patent/CA3105585A1/en active Pending
- 2019-07-17 IL IL280025A patent/IL280025B2/en unknown
-
2023
- 2023-10-02 JP JP2023171327A patent/JP7644190B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019304014B2 (en) | 2022-08-18 |
| IL280025B1 (en) | 2024-10-01 |
| KR102849420B1 (ko) | 2025-08-25 |
| WO2020016302A1 (en) | 2020-01-23 |
| BR112021000467A2 (pt) | 2021-04-06 |
| WO2020016302A8 (en) | 2020-11-12 |
| JP2024001109A (ja) | 2024-01-09 |
| MA53162A (fr) | 2021-05-26 |
| CN112424187B (zh) | 2024-06-21 |
| IL280025A (en) | 2021-03-01 |
| AU2019304014A1 (en) | 2021-03-04 |
| SG11202100240RA (en) | 2021-02-25 |
| MX2021000611A (es) | 2021-04-13 |
| EP3823964A1 (en) | 2021-05-26 |
| CN112424187A (zh) | 2021-02-26 |
| US11149029B2 (en) | 2021-10-19 |
| KR20210033474A (ko) | 2021-03-26 |
| CA3105585A1 (en) | 2020-01-23 |
| CN118580223A (zh) | 2024-09-03 |
| IL280025B2 (en) | 2025-02-01 |
| US20200062737A1 (en) | 2020-02-27 |
| JP7422732B2 (ja) | 2024-01-26 |
| JP7644190B2 (ja) | 2025-03-11 |
| JP2021530526A (ja) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411222B1 (ar) | مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MX2024008497A (es) | Fabricacion de compuestos y composiciones para inhibir la actividad de shp2. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2017010735A (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| PH12018501099A1 (en) | Novel biphenyl compound or salt thereof | |
| CA2875877C (en) | Syk inhibitors | |
| JOP20180113A1 (ar) | مركبات ,تركيبات وطرق | |
| PH12017500281B1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| EA033168B1 (ru) | СТИМУЛЯТОРЫ sGC | |
| PH12017501426A1 (en) | Derivatives of betulin | |
| ZA202308002B (en) | Pyrimidopyran compound | |
| MY176803A (en) | Polymorph of syk inhibitors | |
| ZA201805185B (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| MX2021006544A (es) | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. | |
| MX2018001925A (es) | Composiciones que comprenden compuestos triciclicos heterociclicos. | |
| MY209356A (en) | A xinafoate salt of a jak inhibiting compound | |
| MY185971A (en) | Pyranodipyridine compound | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2021001904A (es) | Formas solidas de benzoxaborol sustituido y composiciones de las mismas. | |
| MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds |